Organon: Humira A ‘Whole Different Animal’ To Other US Biosimilars

US-Based Firm Also In Discussions To Expand Biosimilar Pipeline

 
• By Dean Rudge

Shortly after filing for a high-concentration biosimilar adalimumab product with partner Samsung Bioepis, Organon has provided in-depth commentary for its expectations around the impending formation of the market, forecasting a “free for all” six months post-formation.

Waves crashing against the shoreline at sunset along the Western coast of Oahu
The first wave of Humira biosimilars will launch next year • Source: Alamy/Design Pics Inc

Pharmacy benefit managers are keen for optionality for the impending launch of biosimilar Humira (adalimumab) products next year, in order to see “where the price could potentially spiral to” ahead of a potential “free for all” six months after market formation, according to adalimumab sponsor Organon.

Addressing delegates to the virtual J.P

More from Biosimilars

More from Products